PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 27 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Clinical evidence
A hexane fraction of M. royoc root extract exhibited potent in vitro activity against G. lamblia trophozoites (IC50 = 0.08 μg/mL) without affecting cell viability [PMID:36032741].
M. royoc showed among the highest in vitro efficacy against Cryptosporidium spp. and G. duodenalis [PMID:41817887].
Dichloromethane extract from in vitro cultured roots showed activity against all tested Candida species (except C. glabrata) and oxacillin-resistant Staphylococcus aureus [PMID:20521552].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 36032741 (2022) — A Morinda royoc Root Extract and Fractions Exhibit Antigiardial Activity without Affecting Cell Viability. · Iranian journal of parasitology
- 2.PMID: 41817887 (2026) — Phytoextracts Used in the Treatment of Cryptosporidiosis and Giardiasis: Current State. · Acta parasitologica
- 3.PMID: 20521552 (2010) — Antimicrobial activity of the dichloromethane extract from in vitro cultured roots of Morinda royoc and its main constituents. · Natural product communications
- 4.PMID: 42187731 (2026) — Unlocking Seed Dormancy and Elucidating Storage Behavior in Morinda royoc (Rubiaceae): Crucial Insights for Propagation and Ex Situ Germplasm Conservation. · Biology